Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...

and strength in the weight-loss portfolio suggests it is well-positioned for long-term growth. Wall Street analysts currently have a “Moderate Buy” consensus rating on HIMS stock. However ...

Hims Hard Mints are a discreet alternative to erectile dysfunction pills. They’re created by ... As a result, you cannot buy them over the counter (OTC) — they require a consultation with ...

Hims & Hers (HIMS) went all-in on weight-loss drugs. It bet big on cheaper, compounded versions of blockbuster GLP-1 treatments like ...

The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents. The knockoff surge was led by Hims & Hers Health, the telehealth firm that ...

Shares in telehealth business Hims & Hers Health (HIMS) dropped over 6% today after reports that it and peers are marketing ...

But with GLP-1 sales vanishing, Hims is left banking on generic weight-loss pills and its core business in hair-loss and ED treatments. While that business is solid, it doesn't justify the lofty ...

Hims & Hers is set to continue offering weight-loss pills and personalized weight-loss support, including nutrition plans and coaching. Outside of weight-loss care, the company saw its subscriber ...

Hims & Hers (HIMS) stock took a steep dive ... Instead, the company will focus on weight-loss pills and a generic version of liraglutide — an older GLP-1 drug taken daily instead of weekly ...

Hims and Hers plans to stop selling compounded weight loss drugs after an FDA update. Hims and Hers' stock fell over 19% in after-hours trading on Monday. The FDA removed semaglutide injections ...